- Home
- FLC vs CRVS Comparison
FLC vs CRVS Comparison
Compare FLC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | CRVS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 1.2B |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FLC | CRVS |
|---|---|---|
| Price | $16.77 | $14.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.20 |
| AVG Volume (30 Days) | 23.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.48 | $2.54 |
| 52 Week High | $18.09 | $26.95 |
Technical Indicators
Market Signals| Indicator | FLC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 47.68 |
| Support Level | N/A | $12.95 |
| Resistance Level | $17.68 | $18.73 |
| Average True Range (ATR) | 0.22 | 0.95 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 46.58 | 62.88 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.